KIR3DL2 and primary cutaneous T-cell non-Hodgkin lymphoma: KIR3DL2 mAb identifies the tumor cells in most CTCL patients analyzed and, therefore, represents a valid tool to dynamically evaluate the evolution of the tumor pool during disease evolution as well as the response to treatment (68).